Coronavirus variant found in South Africa paves way for better vaccines | World News - Hindustan Times
close_game
close_game

Coronavirus variant found in South Africa paves way for better vaccines

Bloomberg |
Mar 03, 2021 05:26 PM IST

The variant, identified in South Africa late last year, has taken over as the dominant strain in the nation of 60 million people and has spread to 48 other countries.

South African scientists said their findings that antibodies generated in response to infections with the 501Y.V2 coronavirus variant first found in the country can protect against other strains of the virus may allow for more effective vaccines.

South Africa's Deputy President David Mabuza gestures during a visit to Biovac, a Covid-19 vaccine storage facility, in Midrand, South Africa.(AFP)
South Africa's Deputy President David Mabuza gestures during a visit to Biovac, a Covid-19 vaccine storage facility, in Midrand, South Africa.(AFP)

“If you are actually infected with this variant or you can design a vaccine with this variant it might provide cross-protection against other variants,” Alex Sigal, a faculty member at the African Health Research Institute, said on a webinar on Wednesday. “It might leave the virus with not much room to go. This to us was incredible.”

Hindustan Times - your fastest source for breaking news! Read now.

The variant, identified in South Africa late last year, has taken over as the dominant strain in the nation of 60 million people and has spread to 48 other countries. Initial evidence suggests it’s 50% more transmissible than the original virus and has led to countries including the UK banning flights from South Africa.

Much of the research was done by Krisp, a genetic-sequencing institute in Durban, South Africa. The research did show that antibodies generated in reaction to infections with the original virus were as much as 48% less effective against the new variant, according to data presented on the webinar.

“This is indeed good news for all of us,” South African Health Minister Zweli Mkhize said.

A small trial of AstraZeneca Plc’s vaccine indicated that it had limited effect on preventing mild disease from infection with the 501Y.V2 variant, leading the government to switch to Johnson & Johnson’s shot for its initial vaccinations.

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away! - Login Now!

Get Latest World News along with Latest News from India at Hindustan Times.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, March 29, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On